A Phase Ib Study of Vismodegib and Atezolizumab in Non-Small Cell Lung Cancer
Suspended Phase 1 NCT06616623
Study Description
A Study of the Combination of Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Study Details
- Registry ID:
- NCT06616623
- Conditions:
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Phase:
- Phase 1
- Target Enrollment:
- 24 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.